Jan 2024 $10 M Private placement after listing $10 to $50 million 5
RedHill Biopharma Ltd.: Private sale, Jan 2024 × Investors in this round 5 investors had bought by the notice of Feb 5, 2024: 5 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $10 M of $10 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue $5 million to $25 million
Sales commissions $600,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Israel People named in the notice Adi Frish · Executive Officer Dror Ben-Asher · Executive Officer, Director Gilead Raday · Executive Officer Guy Goldberg · Executive Officer Razi Ingber · Executive Officer Reza Fathi · Executive Officer Rick Scruggs · Executive Officer, Director Alla Felder · Director Eric Swenden · Director Kenneth Reed · Director Ofer Tsimchi · Director Shmuel Cabilly · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round H.C. Wainwright & Co., LLC (CRD 375) · New York, New York Sold in CA, IL, NY, TX Remarks in the notice On fees: “The placement agent (or its designees) also received warrants to purchase up to 600,000 ADSs of the Company, at an exercise price of $1.00 per ADS under Section 4(a)(2) of the Securities Act and/or Regulation D promulgated thereunder.”On the amounts: “"This Form D is being filed in connection with the issuance of warrants to purchase up to 10,000,000 American Depositary Shares (""ADSs"") at an exercise price of $1.00 per ADS, each ADS representing 400 ordinary shares, par value NIS 0.01, of the Company"”Signed by Razi Ingber, Chief Financial Officer. Source: SEC Form D, newest notice filed Feb 5, 2024. Read the notice at the SEC .
equity, options SEC Sep 2023 $4 M Private placement after listing $2 to $10 million 3
RedHill Biopharma Ltd.: Private sale, Sep 2023 × Investors in this round 3 investors had bought by the notice of Oct 12, 2023: 3 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $4 M of $4 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue $25 million to $100 million
Sales commissions $151,643
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Israel People named in the notice Adi Frish · Executive Officer Dror Ben-Asher · Executive Officer, Director Gilead Raday · Executive Officer Guy Goldberg · Executive Officer Razi ingber · Executive Officer Reza Fathi · Executive Officer Rick Scruggs · Executive Officer, Director Alla Felder · Director Eric Swenden · Director Kenneth Reed · Director Ofer Tsimchi · Director Shmuel Cabilly · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round H.C. Wainwright & Co., LLC (CRD 375) · New York, New York Sold in NY Remarks in the notice On fees: “The placement agent (or its designees) also received warrants to purchase up to 258,115 ADSs of the Company at an exercise price of $0.5875 per ADS, each ADS representing 400 ordinary shares, par value NIS 0.01 per share, of the Company.”On the amounts: “"This Form D is being filed in connection with the issuance of warrants to purchase up to 8,603,846 American Depositary Shares (""ADSs"") at an exercise price of $0.47 per ADS, each ASD representing 400 ordinary shares, par value NIS 0.01, of the Company."”Signed by Dror Ben-Asher, Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 12, 2023. Read the notice at the SEC .
equity, options SEC Jul 2023 $3 M Private placement after listing $2 to $10 million 1
RedHill Biopharma Ltd.: Private sale, Jul 2023 × Investors in this round 1 investor had bought by the notice of Aug 7, 2023: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $3 M of $3 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue $25 million to $100 million
Sales commissions $283,695
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Israel People named in the notice Adi Frish · Executive Officer Dror Ben-Asher · Executive Officer, Director Gilead Raday · Executive Officer Guy Goldberg · Executive Officer Razi ingber · Executive Officer Reza Fathi · Executive Officer Alla Felder · Director Eric Swenden · Director Kenneth Reed · Director Ofer Tsimchi · Director Rick Scruggs · Director Shmuel Cabilly · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round H.C. Wainwright & Co., LLC (CRD 375) · New York, New York Sold in NY Remarks in the notice On fees: “The placement agent (or its designees) also received warrants to purchase 168,115 American Depositary Shares at an exercise price of $1.6875 per ADS,each representing 400 ordinary shares, par value NIS 0.01 per share, of the Company.”On the amounts: “This Form D is being filed in connection with the issuance of warrants to purchase up to 1,500,000 ADSs an exercise price of $1.80 per ADS, with each ADS each representing 400 ordinary shares, par value NIS 0.01 per share, of the Company.”Signed by Dror Ben-Asher, Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 7, 2023. Read the notice at the SEC .
equity, options SEC Nov 2021 $5 M Private placement after listing $2 to $10 million 1
RedHill Biopharma Ltd.: Private sale, Nov 2021 × Investors in this round 1 investor had bought by the notice of Nov 22, 2021: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $5 M of $10 M offered; $5 M still to sell
Smallest investment taken $5,000,000
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue $25 million to $100 million
Sales commissions none
Finders' fees $200,000
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Israel People named in the notice Adi Frish · Executive Officer Dror Ben-Asher · Executive Officer, Director Gilead Raday · Executive Officer Guy Goldberg · Executive Officer June Almenoff · Executive Officer Micha Ben Chorin · Executive Officer Reza Fathi · Executive Officer Rick Scruggs · Executive Officer, Director Alla Felder · Director Eric Swenden · Director Kenneth Reed · Director Ofer Tsimchi · Director Shmuel Cabilly · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Network 1 Financial Securities, Inc. (CRD 13577) · Red Bank, New Jersey Sold in no state named, and outside the US Nexpedia Holdings Co., Ltd · Seoul, Korea, Republic Of Sold in no state named, and outside the US Signed by Dror Ben-Asher, Chief Executive Officer. Source: SEC Form D, newest notice filed Nov 22, 2021. Read the notice at the SEC .
equity SEC Oct 2019 $48 M Private placement after listing $10 to $50 million 2
RedHill Biopharma Ltd.: Private sale, Oct 2019 × Investors in this round 2 investors had bought by the notice of Nov 6, 2019: 2 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $48 M of $48 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue $5 million to $25 million
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Israel People named in the notice Adi D Frish · Executive Officer Dror Ben-Asher · Executive Officer, Director Gilead D Raday · Executive Officer Guy D Goldberg · Executive Officer June D Almenoff · Executive Officer Micha D Ben Chorin · Executive Officer Reza D Fathi · Executive Officer Rick D Scruggs · Executive Officer, Director Alla D Felder · Director Eric Swenden · Director Kenneth Reed · Director Nicolas D Weinstein · Director Ofer Tsimchi · Director Shmuel Cabilly · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “A portion of the ADSs were issued at an agreed value of $12 million, as an upfront payment for rights granted to the issuer under an exclusive license agreement”Signed by Micha Ben Chorin, Cfo. Source: SEC Form D, newest notice filed Nov 6, 2019. Read the notice at the SEC .
equity SEC Dec 2013 $3 M No. 1 $2 to $10 million 1
RedHill Biopharma Ltd.: Raise no. 1, Dec 2013 × Investors in this round 1 investor had bought by the notice of Jan 15, 2014: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $3 M of $3 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Up to $1 million
Sales commissions $175,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions as estimates
The company Corporation, incorporated in Israel People named in the notice Adi Frish · Executive Officer · Senior Vice President Business Development and Licensing Dror Ben Asher · Executive Officer, Director · CEO and Chairman of the Board of Directors Gilead Raday · Executive Officer · Senior Vice President Research and Development Guy Goldberg · Executive Officer · Chief Business Officer Ori Shilo · Executive Officer, Director · Deputy Chief Executive Officer Finance and Operations and Director Reza Fathi · Executive Officer · Senior Vice President Research and Development Uri Hananel Aharon · Executive Officer · Chief Accounting Officer Aliza Rotbard · Director · External Director Dan Suesskind · Director Eric Swenden · Director Kenneth Reed · Director Ofer Tsimchi · Director · External Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Roth Capital Partners, LLC (CRD 15407) · New York, New York Sold in NY Stifel, Nicolaus & Company, Incorporated (CRD 793) · New York, New York Sold in NY Remarks in the notice On fees: “Final amount being negotiated and not yet determined.”Signed by Ori Shilo, Deputy CEO Finance and Operations and Director. Source: SEC Form D, newest notice filed Jan 15, 2014. Read the notice at the SEC .
equity, options SEC